Hot COVID-19
Home > News > CENTOGENE, Lufthansa, and Fraport Launch the First Walk-In COVID-19 Testing Facility
Industry Updates New Products Supplier News Upcoming Events business web

CENTOGENE, Lufthansa, and Fraport Launch the First Walk-In COVID-19 Testing Facility

Hits:424   Date: 6/29/2020
CENTOGENE, Lufthansa, and Fraport Launch the First Walk-In COVID-19 Testing Facility in Germany at Frankfurt Airport
* Lufthansa becomes first globally leading airline with a solution for safe and convenient international air travel during this pandemic
* Landmark exclusive cooperation offers testing for passengers departing from or arriving at Frankfurt airport starting immediately
* Innovative concept supports a safe reopening of air travel and further steps towards a new normal for our societies and economies

Cambridge, MA, USA & Rostock/Berlin, Germany, June 29, 2020  (GLOBE NEWSWIRE) – CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, announced today that it has partnered exclusively with Lufthansa and with Fraport, the operator of Frankfurt Airport, to offer COVID-19 testing to passengers flying to and from Frankfurt Airport (FRA). Serving as a blueprint to opening international borders, this first walk-in testing solution in Germany will aid with regulations when entering countries. In many countries (e.g., China), passengers will not be allowed to enter without prior COVID-19 testing. The exclusive partnership for Frankfurt Airport with Lufthansa and Fraport starts immediately, and is expected to run until July 31, 2021.
Passengers flying to or from Frankfurt Airport with Lufthansa will be able to perform the test at a sampling center conveniently located near the main terminal. This can either be completed the day before traveling or with a fast track solution the same day before departure. All results are delivered to the passenger via a secure digital platform and connected to their ticket – providing secured clearance for passengers flying to countries with entrance restrictions. Additionally, passengers can opt into an ID confirmation service, assuring authorities that the passengers’ identities correspond with the test results.
Dr. Volkmar Weckesser, CENTOGENE Chief Information Officer, stated, “Over the past months, global air travel has been critically affected by the COVID-19 pandemic – preventing individuals from traveling home, attending business meetings, and going on trips that were planned months in advance. Through our partnership with Lufthansa and our medical partner Dr. Bauer Laboratoriums GmbH, we can ensure a quick, accurate, and secure end-to-end solution that safely reopens air travel and further supports a return to a new normal for our societies and economies.”
“By opening the test center, we are offering our guests a comfortable opportunity to test themselves for flights abroad or a stay in Germany to avoid quarantine,” said Dr. Björn Becker, Senior Director Product Management Ground & Digital Services at Lufthansa Group. “Even in these challenging times, we are using our innovative strength and strong partnerships with CENTOGENE and Frankfurt Airport to ensure that our customers have a safe and relaxing travel experience.”
Daniela Weiss, Fraport Vice President Duty Management Terminals, said: “We are happy to offer passengers this new service at Frankfurt Airport. This is another example of how Frankfurt Airport, together with its partners, is pioneering the development of innovative passenger services. This service ensures a safe and relaxed travel experience at Germany’s global gateway, even during these times.”
CENTOGENE engages in diagnosis and research around rare diseases transforming real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. Our goal is to bring rationality to treatment decisions and to accelerate the development of new orphan drugs by using our extensive rare disease knowledge, including epidemiological and clinical data, as well as innovative biomarkers. CENTOGENE has developed a global proprietary rare disease platform based on our real-world data repository with approximately 3.0 billion weighted data points from over 530,000 patients representing over 120 different countries as of March 31, 2020.
The Company’s platform includes epidemiologic, phenotypic, and genetic data that reflects a global population, and also a biobank of these patients’ blood samples. CENTOGENE believes this represents the only platform that comprehensively analyzes multi-level data to improve the understanding of rare hereditary diseases, which can aid in the identification of patients and improve our pharmaceutical partners’ ability to bring orphan drugs to the market. As of March 31, 2020, the Company collaborated with 39 pharmaceutical partners covering over 45 different rare diseases.
Tel:+1 (617) 580-2102